JP2008536853A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008536853A5 JP2008536853A5 JP2008506668A JP2008506668A JP2008536853A5 JP 2008536853 A5 JP2008536853 A5 JP 2008536853A5 JP 2008506668 A JP2008506668 A JP 2008506668A JP 2008506668 A JP2008506668 A JP 2008506668A JP 2008536853 A5 JP2008536853 A5 JP 2008536853A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- pharmaceutically acceptable
- acceptable salt
- compound
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67074405P | 2005-04-13 | 2005-04-13 | |
| US74843305P | 2005-12-08 | 2005-12-08 | |
| US11/402,502 US20060235006A1 (en) | 2005-04-13 | 2006-04-12 | Combinations, methods and compositions for treating cancer |
| PCT/US2006/013773 WO2006113304A2 (en) | 2005-04-13 | 2006-04-13 | Combinations, methods and compositions for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008536853A JP2008536853A (ja) | 2008-09-11 |
| JP2008536853A5 true JP2008536853A5 (enExample) | 2009-05-28 |
Family
ID=37109315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008506668A Withdrawn JP2008536853A (ja) | 2005-04-13 | 2006-04-13 | 癌治療のための、組み合わせ、方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20060235006A1 (enExample) |
| EP (1) | EP1868435A4 (enExample) |
| JP (1) | JP2008536853A (enExample) |
| KR (1) | KR20080004495A (enExample) |
| AU (1) | AU2006236812A1 (enExample) |
| BR (1) | BRPI0608176A2 (enExample) |
| CA (1) | CA2604581A1 (enExample) |
| EA (1) | EA200702238A1 (enExample) |
| MX (1) | MX2007012537A (enExample) |
| NO (1) | NO20075087L (enExample) |
| TW (1) | TW200722091A (enExample) |
| WO (1) | WO2006113304A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ513639A (en) | 1999-04-15 | 2004-02-27 | Bristol Myers Squibb Co | Cyclic protein tyrosine kinase inhibitors |
| CN108421044A (zh) | 2005-02-03 | 2018-08-21 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
| WO2006135790A1 (en) * | 2005-06-09 | 2006-12-21 | Bristol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting mutant kit protein |
| BRPI0618042A2 (pt) | 2005-11-04 | 2011-08-16 | Wyeth Corp | usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica |
| US20090099197A1 (en) * | 2005-11-15 | 2009-04-16 | Bristol-Myers Squibb Company | Methods of Identifying and Treating Individuals Exhibiting MDR-1 Overexpression With Protein Tyrosine Kinase Inhibitors and Combinations Thereof |
| CN102861338A (zh) * | 2006-04-05 | 2013-01-09 | 诺瓦提斯公司 | 用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合 |
| MX2008012903A (es) * | 2006-04-07 | 2008-10-13 | Novartis Ag | Uso de inhibidores de c-src en combinacion con un compuesto de pirimidilaminobenzamida para el tratamiento de la leucemia. |
| US20080119463A1 (en) * | 2006-11-16 | 2008-05-22 | Wyeth | 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML) |
| WO2008064004A2 (en) * | 2006-11-16 | 2008-05-29 | Wyeth | 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml) |
| WO2008089135A2 (en) * | 2007-01-12 | 2008-07-24 | University Of South Florida | Identification of biomarkers predictive of dasatinib effects in cancer cells |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| ES2396366T3 (es) * | 2007-12-10 | 2013-02-21 | Concert Pharmaceuticals Inc. | Inhibidores heterocíclicos de quinasas |
| CN102641270A (zh) | 2008-06-17 | 2012-08-22 | 惠氏有限责任公司 | 含有hki-272和长春瑞滨的抗肿瘤组合 |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| US8669273B2 (en) * | 2008-08-04 | 2014-03-11 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| US20100233172A1 (en) * | 2008-12-16 | 2010-09-16 | Bristol-Myers Squibb Company | Methods of inhibiting quiescent tumor proliferation |
| LT2769737T (lt) * | 2009-07-20 | 2017-06-26 | Bristol-Myers Squibb Company | Anti-ctla4 antikūno derinys su etopozidu, skirtas sinerginiam proliferacinių ligų gydymui |
| JP2013505968A (ja) * | 2009-10-01 | 2013-02-21 | シーエスエル、リミテッド | フィラデルフィア染色体陽性白血病の治療方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011029A (en) * | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| US7125875B2 (en) * | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| NZ513639A (en) * | 1999-04-15 | 2004-02-27 | Bristol Myers Squibb Co | Cyclic protein tyrosine kinase inhibitors |
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| BR0209647A (pt) * | 2001-05-16 | 2004-07-27 | Novartis Ag | Combinação que compreende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e um agente quimioterapêutico |
| EP1534862A4 (en) * | 2002-08-07 | 2007-10-10 | Exelixis Inc | RABGGT MODULATORS AND METHODS OF USE THEREOF |
| US20050009891A1 (en) * | 2003-07-09 | 2005-01-13 | Lee Francis Y. | Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases |
| MY144177A (en) * | 2004-02-04 | 2011-08-15 | Novartis Ag | Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide. |
| US7491725B2 (en) * | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| TW200628156A (en) * | 2004-11-04 | 2006-08-16 | Bristol Myers Squibb Co | Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases |
-
2006
- 2006-04-12 US US11/402,502 patent/US20060235006A1/en not_active Abandoned
- 2006-04-13 JP JP2008506668A patent/JP2008536853A/ja not_active Withdrawn
- 2006-04-13 KR KR1020077023422A patent/KR20080004495A/ko not_active Withdrawn
- 2006-04-13 MX MX2007012537A patent/MX2007012537A/es not_active Application Discontinuation
- 2006-04-13 EA EA200702238A patent/EA200702238A1/ru unknown
- 2006-04-13 TW TW095113103A patent/TW200722091A/zh unknown
- 2006-04-13 CA CA002604581A patent/CA2604581A1/en not_active Abandoned
- 2006-04-13 WO PCT/US2006/013773 patent/WO2006113304A2/en not_active Ceased
- 2006-04-13 BR BRPI0608176-2A patent/BRPI0608176A2/pt not_active IP Right Cessation
- 2006-04-13 AU AU2006236812A patent/AU2006236812A1/en not_active Abandoned
- 2006-04-13 EP EP06749971A patent/EP1868435A4/en not_active Withdrawn
-
2007
- 2007-10-09 NO NO20075087A patent/NO20075087L/no not_active Application Discontinuation
-
2008
- 2008-10-23 US US12/256,771 patent/US20090054415A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009502743A5 (enExample) | ||
| JP2021063088A5 (enExample) | ||
| JP2021526132A5 (enExample) | ||
| JP2024516371A5 (enExample) | ||
| JP2021191784A5 (enExample) | ||
| JP2009545527A5 (enExample) | ||
| JP2007145875A5 (enExample) | ||
| JP2006514012A5 (enExample) | ||
| JP2018507914A5 (enExample) | ||
| IL193099A (en) | Use of ferric citrate-containing preparations in the preparation of chronic kidney disease drugs | |
| JP2013542247A5 (enExample) | ||
| JP2013525444A5 (enExample) | ||
| JP2010515715A5 (enExample) | ||
| JP2010525056A5 (enExample) | ||
| JP2006182786A5 (enExample) | ||
| JP2007504174A5 (enExample) | ||
| JP2015523397A5 (enExample) | ||
| CL2007003690A1 (es) | Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas. | |
| JP2013522326A5 (enExample) | ||
| JP2008539267A5 (enExample) | ||
| JP2008539268A5 (enExample) | ||
| JP2007510667A5 (enExample) | ||
| JP2015193630A5 (enExample) | ||
| JP2008514577A5 (enExample) | ||
| JP2012522842A5 (enExample) |